MedTrace Logo

Multiple Ascending Doses of Globalagliatin Hydrochloride in Type 2 Diabetes Mellitus

NCT03414892 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2020-01-03

No results posted yet for this study

Summary

This is a phase I placebo-controlled study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of Globalagliatin Hydrochloride (SY-004) after Multiple Ascending Doses in patients with Type 2 Diabetes Mellitus (T2DM).

Conditions

Interventions

DRUG

Globalagliatin Hydrochloride

once daily, oral

DRUG

Placebo

once daily, oral

Sponsors & Collaborators

  • Yabao Pharmaceutical Group

    lead INDUSTRY

Principal Investigators

  • Lei Yang · Yabao pharmaceutical Group Co.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-03
Primary Completion
2019-01-04
Completion
2019-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03414892 on ClinicalTrials.gov